Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 885270-86-0 | MDL No. : | MFCD08234738 |
Formula : | C11H20N2O2 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | BGUYAMZPJMTFRU-UHFFFAOYSA-N |
M.W : | 212.29 | Pubchem ID : | 46835579 |
Synonyms : |
|
Num. heavy atoms : | 15 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.91 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 65.74 |
TPSA : | 41.57 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.1 cm/s |
Log Po/w (iLOGP) : | 2.66 |
Log Po/w (XLOGP3) : | 0.7 |
Log Po/w (WLOGP) : | 0.46 |
Log Po/w (MLOGP) : | 1.15 |
Log Po/w (SILICOS-IT) : | 1.05 |
Consensus Log Po/w : | 1.2 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -1.4 |
Solubility : | 8.47 mg/ml ; 0.0399 mol/l |
Class : | Very soluble |
Log S (Ali) : | -1.15 |
Solubility : | 15.0 mg/ml ; 0.0707 mol/l |
Class : | Very soluble |
Log S (SILICOS-IT) : | -1.82 |
Solubility : | 3.19 mg/ml ; 0.015 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.71 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | N/A |
GHS Pictogram: |
![]() |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
8% | To a 5 mL screw-cap reaction tube was added compound A-9 4-(7-(difluoromethyl)-5-(3,4-dimethoxyphenyl)-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrimidin-2-yl)benzoic acid (20.0 mg, 0.045 mmol), <strong>[885270-86-0]tert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate</strong> (18.98 mg, 0.089 mmol), HATU (18.7 mg, 0.049 mmol), NMP (0.500 ml), and Huenig's Base (6.00 ul, 0.044 mmol). The reaction mixture was stirred at 30 C. overnight. The material was purified by LC/MS using HPLC condition III. The fractions containing product were combined and concentrated in vacuo. The resulting material was then taken up in ethanol (1.0 ml) and 50% trifluoroacetic acid in DCM (1.0 ml, 4.00 mmol) and the mixture stirred at RT for 1 h. The mixture was then concentrated in vacuo to give compound ER-895080 as a yellow solid (2.40 mg, 8% yield). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
80% | With triethylamine; In dichloromethane; at 20℃; for 0.5h; | A mixture of 4,6-dichloro-8-fluoro-7-(2-fluoro-6- methoxyphenyl)quinazoline (100 mg, 0.29 mmol), tert-butyl 2,6-diazaspiro[3.4]octane- 6-carboxylate (80 mg, 0.37 mmol), TEA (60 mg, 0.58 mmol) and dichloromethane (5 mL) was stirred at RT for 0.5 h. The mixture was quenched with saturated NaHCO3 solution and partitioned between water and ethyl acetate. The organic layer was dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (ethyl acetate/petroleum ether = 1:5) to afford the desired product (120 mg, 80% yield) as white solid. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine; In dimethyl sulfoxide; at 120℃;Sealed tube; | In a sealed tube, 7-fluoro-9-methyl-2-(2-methyl-[l,2,4]triazolo[l,5-b]pyridazin-6-yl)-4H- pyrido[l,2-a]pyrimidin-4-one (Intermediate (VI-3), 30 mg, 0.097 mmol), TEA (34.2 mg, 47 mu, 0.338 mmol, 5 eq.) and <strong>[885270-86-0]tert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate</strong> (61.6 mg, 0.290 mmol, 3 eq.) were stirred in DMSO (1.5 ml) at 120C over the night. The precipitating product was filtered and triturated with diethylether. The isolated solid was then treated following the General Procedure 1 for Boc deprotection to afford the product 7-(2,7-diazaspiro[3.4]octan-2-yl)-9-methyl-2-(2-methyl-[l,2,4]triazolo[l,5- b]pyridazin-6-yl)pyrido[l,2-a]pyrimidin-4-one;2,2,2-trifluoroacetic acid (2.5mg, 0.005 mmol, 34.8 % yield) as a brown solid. MS m/z 403.2 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
80% | With palladium diacetate; 4,5-bis(diphenylphos4,5-bis(diphenylphosphino)-9,9-dimethylxanthenephino)-9,9-dimethylxanthene; sodium t-butanolate; In 1,4-dioxane; at 100℃; for 2h;Inert atmosphere; Schlenk technique; | Preparation of intermediate BT 5 In a Shlenck reactor, a solution of <strong>[885270-86-0]6-Boc-2,6-diazaspiro[3.4]octane</strong> (CAS [885270-86- 0], 0.5g, 2.36 mmol), l-Bromo-4-(trifluoromethoxy)benzene (CAS [407-14-7], 525 mu, 3.53 mmol) and sodium terbutoxide (0.453 g, 4.71 mmol) in 1,4-dioxane (25 mL) was purged with N2. Then Palladium (II) acetate (52.9 mg, 0.236 mmol) and Xantphos (0.136 g, 0.236 mmol) were added, the mixture was purged again with N2 and stirred at 10 100C for 2h. The mixture was combined filtered on a pad of Celite. The cake was washed with EtOAc and the fitlrate was evaporated in vacuo to give 1.2 g as a brown solid. The residue was purified by preparative LC (irregular SiOH, 15-40 muiotaeta, 50 g, Merck, dry loading (Celite), mobile phase gradient: from Heptane/EtOAc from 95/5 to 60/40) to give 0.756 g of intermediate BT as off-white solid (80%). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
69% | With triethylamine; In dichloromethane; at 0 - 20℃; for 21h; | At 0 C, Triethylamine (2.1 mL, 15.0 mmol) with benzyl chloroformate (2.2 mL, 15.0 mmol) Adding to a solution of <strong>[885270-86-0]2,7-diazaspiro[3.4]octane-7-carboxylic acid tert-butyl ester</strong> (1.6 g, 7.5 mmol) in dichloromethane (20 mL) the reaction was carried out at room temperature for 21 hours. Water (5 mL) was added, and the organic phase was washed with a saturated sodium chloride solution (5 mL×2). Dry over anhydrous sodium sulfate and concentrate by suction filtration. The residue was subjected to silica gel column chromatography [petroleum ether/ethyl acetate (v / v) = 3 / 1] purification, The title compound (1.8 g, yield 69%) |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
80% | With sodium hydrogencarbonate; In water; at 20℃; for 1.5h; | Sodium bicarbonate (10.0 g, 119 mmol)Add to a solution of 2,7-diazaspiro[3.4]octane-7-carboxylic acid tert-butyl ester oxalate (3.0 g, 9.9 mmol) in water (10 mL)The reaction was carried out at room temperature for 1.5 hours. Extracted with dichloromethane/methanol (v/v = 9/1, 80 mL x 3),The combined organic phases were washed with a saturated sodium chloride solution (50 mL×2). Dry over anhydrous sodium sulfate and concentrate by suction filtration.The title compound was obtained (1.68 g, yield 80%). It is a yellow oil. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With triethylamine; | Commercially available /er/-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate was treated with MsCl in the presence of TEA to afford tert- butyl 2-(methylsulfonyl)-2,6- diazaspiro[3.4]octane-6-carboxylate which was next treated with TFA in DCM (80% v/v) to afford Amine Intermediate 15 which was used without purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Example 15 2-((2-ethyl-5-(6-(3-hydroxyazetidine-1-carbonyl)-2,6-diazaspiro[3.4]octan-2-yl)pyrazolo[1,5-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile (Compound 15) Starting from intermediate 1 (100 mg, 0.22 mmol) and proceeding in analogy to preparation Example 11, using <strong>[885270-86-0]tert-butyl 2,6-diazaspiro[3.4]octane-6-carboxylate</strong> to afford the title Compound 15 (70 mg, 55% over 4 steps) as a pale brown solid. 1H NMR (400 MHz, CDCl3) delta 8.51-8.50 (d, J=7.6 Hz, 1H), 8.16-8.13(m, 2H), 7.18-7.14(m, 2H), 6.20(d, J=7.6 Hz, 1H), 5.89(s, 1H), 4.62-4.59(m, 1H), 4.28-4.14(m, 2H), 3.96-3.89(m, 4H), 3.86-3.83(m, 2H), 3.57(s, 3H), 3.44(t, J=6.8 Hz, 2H), 2.77(q, J=7.6 Hz, 2H), 2.15(t, J=6.8 Hz, 2H), 1.43-1.23(m, 5H). LC-MS: m/z=587.3 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
25% | General procedure: To a stirred solution of 6-(2-fluoroethyl)-2,6-diazaspiro[3.4]octane (Intermediate X11) (0.107 g, 0.640 mmol) and Et3N (0.089 mL, 0.640 mmol) in DCM (2 mL) was added 5-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)amino)-1-((2-(trimethylsilyl)ethoxy)- methyl)-1H-1,2,4-triazole-3-sulfonyl chloride (Intermediate B4) (0.205 g, 0.438 mmol) in DCM (4 mL). The reaction was stirred at RT for 90 min then concentrated in vacuo. The residue was redissolved in 4 M HCl in dioxane (3 mL) and stirred for 16 h. The reaction mixture was concentrated in vacuo and the crude product was purified by acidic prep HPLC (20-50% MeOH in water) to afford the title compound (23 mg, 11%) as a white solid.LCMS m/z 461.1 (M+H)+(ES+).1H NMR (DMSO-d6) d 13.25 (s, 1H), 9.01 (s, 1H), 6.98 (s, 1H), 4.50 (dt, J = 47.4, 4.8 Hz, 2H), 3.95 - 3.82 (m, 4H), 2.87 - 2.77 (m, 5H), 2.76 - 2.72 (m, 1H), 2.71 - 2.59 (m, 8H), 1.98 (p, J = 7.4 Hz, 4H), 1.88 (t, J = 7.1 Hz, 2H). |
A763978[ 1841081-35-3 ]
tert-Butyl 2,6-diazaspiro[3.4]octane-6-carboxylate hydrochloride
Reason: Free-salt
[ 250275-15-1 ]
cis-2-Boc-Hexahydropyrrol[3,4-c]pyrrole
Similarity: 0.98
[ 199174-29-3 ]
(R)-tert-Butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Similarity: 0.98
[ 199175-10-5 ]
(S)-1-Boc-3-(Aminomethyl)pyrrolidine
Similarity: 0.98
[ 141449-85-6 ]
tert-Butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
Similarity: 0.98
[ 270912-72-6 ]
tert-Butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Similarity: 0.98
[ 250275-15-1 ]
cis-2-Boc-Hexahydropyrrol[3,4-c]pyrrole
Similarity: 0.98
[ 199174-29-3 ]
(R)-tert-Butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Similarity: 0.98
[ 199175-10-5 ]
(S)-1-Boc-3-(Aminomethyl)pyrrolidine
Similarity: 0.98
[ 141449-85-6 ]
tert-Butyl hexahydropyrrolo[3,4-c]pyrrole-2(1H)-carboxylate
Similarity: 0.98
[ 270912-72-6 ]
tert-Butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Similarity: 0.98
[ 1420852-13-6 ]
tert-Butyl 3-(1-aminoethyl)azetidine-1-carboxylate
Similarity: 0.94
[ 236406-55-6 ]
2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane
Similarity: 0.92
[ 896464-16-7 ]
tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate
Similarity: 0.92
[ 152537-03-6 ]
tert-Butyl 3-(2-hydroxyethyl)azetidine-1-carboxylate
Similarity: 0.92
[ 1023301-84-9 ]
tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride
Similarity: 0.90
[ 199174-29-3 ]
(R)-tert-Butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Similarity: 0.98
[ 199175-10-5 ]
(S)-1-Boc-3-(Aminomethyl)pyrrolidine
Similarity: 0.98
[ 270912-72-6 ]
tert-Butyl 3-(aminomethyl)pyrrolidine-1-carboxylate
Similarity: 0.98
[ 236406-49-8 ]
tert-Butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate
Similarity: 0.96
[ 274692-08-9 ]
(S)-tert-Butyl 3-(2-aminoethyl)pyrrolidine-1-carboxylate
Similarity: 0.94
[ 236406-49-8 ]
tert-Butyl 2,7-diazaspiro[4.4]nonane-2-carboxylate
Similarity: 0.96
[ 236406-55-6 ]
2-(tert-Butoxycarbonyl)-2,7-diazaspiro[3.5]nonane
Similarity: 0.92
[ 236406-39-6 ]
8-Boc-2,8-Diazaspiro[4.5]decane
Similarity: 0.92
[ 896464-16-7 ]
tert-Butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate
Similarity: 0.92
[ 336191-17-4 ]
tert-Butyl 2,8-diazaspiro[4.5]decane-2-carboxylate
Similarity: 0.92